Imatinib Mesylate Tablets 100 mg
Recall D-0124-2021, part of FDA recall event 86749. See Shilpa Medicare's company page.
Shilpa Medicare Limited started this Class II drug recall on Dec 8, 2020 (voluntary: firm initiated); FDA lists it as terminated, terminated Mar 11, 2022.
- Classification: Class II
- Started: Dec 8, 2020
- Status: Terminated
- Products in this event: 6
CGMP Deviations
- Product
- Imatinib Mesylate Tablets 100 mg, Rx Only, 90-count Bottle, Manufactured by: Shilpa Medicare Limited, India, Distributed by: Armas Pharmaceuticals Inc., Manalapan, NJ 07726, NDC 72485-202-90.
- Quantity
- 2611 bottles
- Lots and codes
- Lot #s: 7S10033B, 7S10033A, 7S10031A, Exp. 02/28/2021.
- Distribution
- Nationwide in the U.S.
- Recalling firm
- Shilpa Medicare Limited, Polepally, Jadcherla, N/A, India
- How the firm notified
- Letter
- FDA classified
- Dec 9, 2020
- Azacitidine for Injection 100 mg/vial, For Subcutaneous and Intravenous Use Only, Rx Only, One Single Dose Vial,…D-0122-2021 · Class II · Dec 8, 2020 · Terminated
- Imatinib Mesylate Tablets 400 mg, Rx Only, 30-count Bottle, Manufactured by: Shilpa Medicare Limited, India,…D-0125-2021 · Class II · Dec 8, 2020 · Terminated
- Azacitidine for Injection 100 mg/vial, For Subcutaneous and Intravenous Use Only, Rx Only, One Single Dose Vial,…D-0123-2021 · Class II · Dec 8, 2020 · Terminated
- Docetaxel Injection USP 160 mg/8mL (20 mg/mL), For Intravenous Infusion Only, Rx Only, 8 mL Single Use Vial, Cytotoxic…D-0126-2021 · Class II · Dec 8, 2020 · Terminated
- Busulfan Injection 60 mg/10 mL (6 mg/mL), For Intravenous Infusion Only, Must be diluted before use, Single Dose Vial,…D-0121-2021 · Class II · Dec 8, 2020 · Terminated
Newest first, one product per recall event; search them all
- PEMRYDI RTU(pemetrexed injection), 500 mg/50 mL (10 mg/mL), Single-dose vial, Rx only, Manufactured by: Zydus…D-0765-2026 · Class II · Jul 29, 2026 · Ongoing
FDA's weekly Enforcement Report, as openFDA publishes it. A recall is classified by how likely the product is to cause harm: Class I is the most serious. openFDA drug enforcement reports